Enhanced bioavailability and short-term safety of a micellar green tea extract formulation co-delivered with N-acetylcysteine: a randomized crossover study in healthy adults
Frontiers in Nutrition · 23.09.2026 · 13
DOI: 10.3389/fnut.2026.1940156 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Frontiers in Nutrition, online erschienen am 23.09.2026. Verfasst von Yiming Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: ISURA, Clinical Research, Burnaby, BC, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Green tea catechins, particularly epigallocatechin gallate (EGCG), the principal polyphenol in green tea ( Camellia sinensis ), possess diverse bioactivity but suffer from poor absorption and rapid metabolism, leading to very limited oral bioavailability. To address these challenges, this study investigated the pharmacokinetics, safety, and tolerability of LipoMicel ® GTNAC ® (LGT), a novel lipid-based green tea extract formulation co- delivered with N-acetylcysteine (NAC), compared with a standard green tea formulation (SGT) in healthy adults.
Methods
The study comprised two parts: a randomized, double-blind, crossover pharmacokinetic trial in 16 healthy adults comparing LGT 330 mg with SGT 330 mg and SGT 660 mg, followed by a 30-day open-label, single-arm safety study evaluating LGT 1,320 mg/day in 13 participants.
Results
For EGCG, LGT significantly increased baseline-adjusted systemic exposure compared with dose-matched SGT, producing a 4.2-fold higher iAUC₀–₂₄ (1857 ± 1,479 vs. 443 ± 1,570 ng·h/mL; p = 0.032) and a 3.0-fold higher iC max (267 ± 235 vs. 88.6 ± 60.0 ng/mL; p = 0.037). No clinically significant adverse events or clinically meaningful changes in blood chemistry were observed during the 30-day safety phase.
Conclusion
These findings demonstrate that LGT significantly enhances systemic EGCG exposure while remaining well tolerated for over 30 days in healthy adults. Larger and longer-term studies are warranted to determine whether improved EGCG exposure translates into clinically meaningful health benefits. Clinical trial registration https://clinicaltrials.gov/ , registration number NCT06971536.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ISURA, Clinical Research, Burnaby, BC, Canada.
- Factors Group R&D, Burnaby, BC, Canada.
- Academy of Integrative and Holistic Medicine, San Diego, CA, United States.
- Food, Nutrition and Health Program, University of British Columbia, Vancouver, BC, Canada.
- School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
- InovoBiologic Inc., Calgary, AB, Canada.
Zitieren
APA
Zhang, Y., Ibi, A., Kuo, Y. C., Do, P., Du, M., Roh, Y. S., Gahler, R., Hardy, M., Wood, S., Chang, C., & Solnier, J. (2026). Enhanced bioavailability and short-term safety of a micellar green tea extract formulation co-delivered with N-acetylcysteine: a randomized crossover study in healthy adults. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1940156
Vancouver
Zhang Y, Ibi A, Kuo YC, Do P, Du M, Roh YS, et al. Enhanced bioavailability and short-term safety of a micellar green tea extract formulation co-delivered with N-acetylcysteine: a randomized crossover study in healthy adults. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1940156
BibTeX
@article{Zhang2026,
author = {Zhang, Yiming and Ibi, Afoke and Kuo, Yun Chai and Do, Peony and Du, Min and Roh, Yoon Seok and Gahler, Roland and Hardy, Mary and Wood, Simon and Chang, Chuck and Solnier, Julia},
title = {Enhanced bioavailability and short-term safety of a micellar green tea extract formulation co-delivered with N-acetylcysteine: a randomized crossover study in healthy adults},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1940156}
}
EUVIMED